Elevated inflammation markers in pheochromocytoma compared to other forms of hypertension

NeuroImmunoModulation

Volumn 14, Issue 1, 2007, Pages 57-64

  Zelinka, Tomáš ^a,b   Petrák, Ondřej ^a   Štrauch, Branislav ^a   Holaj, Robert ^a   Kvasnička, Jan ^a   Mazoch, Jiří ^a   Pacák, Karel ^b   Widimský Jr , Jiří ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Catecholamines; Inflammation; Pheochromocytoma

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CATECHOLAMINE; FIBRINOGEN; OROSOMUCOID; PREALBUMIN; TRANSFERRIN;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PHEOCHROMOCYTOMA; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT;

ADRENAL GLAND NEOPLASMS; ADULT; ALPHA 1-ANTITRYPSIN; ALPHA-MACROGLOBULINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; FIBRINOGEN; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; INFLAMMATION; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; OROSOMUCOID; PHEOCHROMOCYTOMA; PLATELET COUNT; PREALBUMIN; TRANSFERRIN;

EID: 34548367509     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107289     Document Type: Article

References (50)

1. Lenders JW, Eisenhofer G, Mannelli M, Pacak K: Pheochromocytoma. Lancet 2005;366:665-675.
2. Manger WM: An overview of pheochromocytoma: history, current concepts, vagaries and diagnostic challenges. Ann NY Acad Sci 2006;1073:1-20.
3. Elenkov IJ, Iezzoni DG, Daly A, Hartus AG, Chrousos GP: Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation 2005;12:255-269.
4. Black PH, Garbutt LD: Stress, inflammation and cardiovascular disease. J Psychosom Res 2002;52:1-23.
5. Benschop RJ, Rodriguez-Feuerhahn M, Schedlowski M: Catecholamine-induced leukocytosis: early observations, current research and future directions. Brain Behav Immun 1996;10:77-91.
6. Larsson PT, Wallén NH, Hjemdahl P: Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 1994;89:1951-1957.
7. Kjeldsen SE, Weder AB, Egan B, Neubig R, Zweifler AJ, Julius S: Effect of circulating epinephrine on platelet function and hematocrit. Hypertension 1995;25:1096-1105.
8. Levine SP, Towell BL, Suarez AM, Knieriem LK, Harris MM, George JN: Platelet activation and secretion associated with emotional stress. Circulation 1985;71:1129-1134.
9. Viles-Gonzales JF, Fuster V, Badimon JJ: Links between inflammation and thrombogenicity in atherosclerosis. Curr Mol Med 2006;6:489-499.
10. Kang JM, Lee WJ, Kim WB, Kim TY, Koh JM, Hong SJ, Huh J, Ro JY, Chi HS, Kim MS: Systemic inflammatory syndrome and hepatic inflammatory cell infiltration caused by an interleukin-6 producing pheochromocytoma. Endocr J 2005;52:193-198.
11. Shinizu C, Kubo M, Takano K, Takano A, Kijima H, Saji H, Katsuyama I, Sasano H, Koike T: Interleukin-6 (IL-6) producing pheochromocytoma: direct IL-6 suppression by non-steroidal anti-inflammatory drugs. Clin Endocrinol 2001;54:405-410.
12. Savastos N, Theodossiades G, Malaktari S, Archimandritis AJ: Persistent neutrophilia as a preceding symptom of pheochromocytoma (letter). J Clin Endocrinol Metab 2005;90:2471.
13. Sawka AM, Kudva YC, Singh R, Young F Jr: Authors' response: persistent neutrophilia as a preceeding symptom of pheochromocytoma. J Clin Endocrinol Metab 2005;90:2471.
14. Catena C, Lapenna R, Broselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Secchi LA: Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006;91:3457-3463.
15. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R: Metabolic syndrome: a comprehensive perspective based on interaction between obesity, diabetes and inflammation. Circulation 2005;111:1448-1454.
16. Cottone S, Mulè G, Nardi E, Vadalà A, Guarneri M, Brilotta C, Arsena R, Palermo A, Riccobene R, Cerasola G: Relation of C-reactive protein to oxidative stress and to endothelial activation in essential hypertension. Am J Hypertens 2006;19:313-318.
17. Weber KT: A neuroendocrine-immune interface: the immunostimulatory state of aldosteronism. Herz 2003;28:692-701.
18. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes Mellitus. Diabetes Care 2001;24(suppl 1):S5-S20.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
20. Pickup JC: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27:813-823.
21. French EB, Steel CM, Aitchison WR: Studies on adrenaline-induced leucocytosis in normal man. II. The effects of a α- and β-adrenergic blocking agents. Br J Haematol 1971;21:423-428.
22. Baumann H, Gauldie J: The acute phase response. Immunol Today 1994;15:74-80.
23. Spengler RN, Allen RM, Remick DG, Strie ter RM, Kunkel SL: Stimulation of α-adrenergic receptor augments the production of macrophage derived tumor necrosis factor. J Immunol 1990;145:1430-1434.
24. Severn A, Rapson NT, Hunter CA, Liew FY: Regulation of tumor necrosis factor production by adrenaline and β-adrenergic agonists. J Immunol 1992;148:3441-3445.
25. Van der Poll T, Coyle SM, Braxton CC, Lowry SF: Epinephrine inhibits tumor necrosis factor-α and potentiates interleukin 10 production during human endotoxinemia. J Clin Invest 1996;97:713-719.
26. Mohamed-Ali V, Flower L, Sethi J, Hotamisligil G, Gray R, Humphries SE, York DA, Pinkney J: β-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab 2001;86:5864-5869.
27. Navab M, Ananthramaiah GM, Reddy ST, van Lenten BJ, Ansell BJ, Hama S, Hough G, Bachii E, Grijalva VR, Wagner A, Shaposhnik Z, Fogelman AM: The double jeopardy of HDL. Ann Med 2005;37:173-178.
28. Wang TJ, Nam BH, Wilson PW, Wolf PA, Levy D, Polak JF, D'Agostino RB, O'Donnell CJ: Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2002;22:1662-1667.
29. Magyar MT, Szikszai Z, Balla J, Valikovics A, Kappelmayer J, Imre S, Balla G, Jeney V, Csiba L, Bereczki D: Early-onset carotid atherosclerosis is associated with increased intimamedia thickness and elevated serum levels of inflammatory markers. Stroke 2003;34:58-63.
30. Makita S, Nakamura M, Hiramori K: The association of C-reactive protein levels with carotid intima-media complex thickness and plaque formation in the general population. Stroke 2005;36:2138-2142.
31. Corrado E, Rizzo M, Tantillo R, Muratori I, Bonura F, Vitale G, Novo S: Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. Stroke 2006;37:482-486.
32. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28.
33. Mora S, Rifai N, Buring JE, Ridker PM: Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation 2006;114:381-387.
34. Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, Peters RJ, Jukema JW, Day NE, Kastelein JJ, Khaw KT: C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006;187:415-422.
35. Paramo JA, Beloqui O, Roncal C, Benito A, Orbe J: Validation of plasma fibrinogen as a marker of carotid atherosclerosis in subjects free of clinical cardiovascular disease. Haematologica 2004;89:1226-1231.
36. Fibrinogen Studies Collaboration: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-1809.
37. Loimaala A, Rontu R, Vuori I, Mercuri M, Lehtimäki T, Nenonen A, Bond MG: Blood leukocyte count is a risk factor for intimamedia thickening and subclinical carotid atherosclerosis in middle-aged man. Atherosclerosis 2006;188:263-369.
38. Cardellini M, Marini MA, Frontoni S, Hri bal ML, Andreozzi F, Perticone F, Federici M, Lauro D, Sesti G: Carotid artery intima-media thickness is associated with insulin-mediated glucose disposal in nondiabetic normotensive offspring of type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007;292:E347-E352.
39. Huang ZS, Jeng JS, Wang CH, Yip PK, Wu TH, Lee TK: Correlations between peripheral differential leukocyte counts and carotid atherosclerosis in non-smokers. Atherosclerosis 2001;158:431-436.
40. Kannel WB, Anderson K, Wilson PWF: White blood cell count and cardiovascular disease. JAMA 1992;267:1253-1256.
41. Haim M, Boyko V, Goldbourt U, Battler A, Behar S: Predictive value of elevated white blood cell count in patients with preexisting coronary heart disease. Arch Intern Med 2004;164:433-439.
42. Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, Renlund DG, Muhlestein JB; Intermountain Heart Collaborative Study Group: Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 2005;45:1638-1643.
43. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF: Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991;84:613-617.
44. Olsen MH, Christensen MK, Hansen TW, Gustafsson F, Rasmussen S, Wachtell C, Borch-Johnsen K, Ibsen H, Jørgensen T, Hildebrandt P: High-sensitive C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional risk factors. J Hypertens 2006;24:655-661.
45. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
46. Miller M, Zhan M, Havas S: High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 2005;165:2063-2068.
47. Bernini G, Franzoni F, Galetta F, Moretti A, Taurino C, Bardini M, Santoro G, Ghiadoni L, Bernini M, Salvetti A: Carotic vascular remodelling in patients with pheochromocytoma. J Clin Endocrinol Metab 2006;91:1754-1760.
48. Pivonello R, Faggiano A, Lombardi G, Colao A: The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am 2005;34:327-339.
49. Bornstein SR, Ehrhart-Bornstein M, Gonzalez-Hernandez J, Schroder S, Scherbaum WA: Expression of interleukin-1 in human pheochromocytoma. J Endocrinol Invest 1996;19:693-698.
50. Kontogeorgos G, Scheithauer BW, Kovacs K, Horvath E, Melmed S: Growth factors and cytokines in paragangliomas and pheochromocytomas, with special reference to sustentacular cells. Endocr Pathol 2002;13:197-206.